ライフサイエンスコーパス: oestrogen receptor

1 ifen metabolites that most strongly bind the oestrogen receptor.

2 d a small effect on the binding affinity for oestrogen receptor.

3 r4.1 and glutamate transporter 1 via genomic oestrogen receptors.

4 ptors (beta-AR) and independently of classic oestrogen receptors.

5 CAV1, the matrix metalloproteinase MMP14 and oestrogen receptors.

6 the glucocorticoid and progesterone, but not oestrogen, receptors.

7 o-endoscopic imaging of neurons positive for oestrogen receptor 1 (ESR1) in either the medial preopti

8 fied a subset of VMHvl neurons marked by the oestrogen receptor 1 (Esr1), and investigated their role

9 Our data also show that oestrogen receptor 1 (Esr1)-expressing cells in the COAp

10 he lateral preoptic area (LPOA) that express oestrogen receptor 1 (LPOA(ESR1) neurons) and, when acti

11 Oestrogen receptor 1-expressing (Esr1(+)) neurons in the

12 For oestrogen receptor, 1 x FNAB had the best performance, w

13 ut a very different pattern was observed for oestrogen receptor 2 (ER2).

14 have tumours with variable concentrations of oestrogen-receptors, a surrogate for other biomarkers as

15 n these VMHvl neurons by directly recruiting oestrogen receptor-a (ERa) to the Mc4r gene.

16 Ms) and downregulators (SERDs) also modulate oestrogen receptor activity in both health and disease.

17 rogen receptor corepressor REA (repressor of oestrogen receptor activity), can repress androgen recep

18 through regulation of androgen receptor and oestrogen receptor activity.

19 In addition to its activity as an oestrogen receptor agonist/antagonist, tamoxifen also mo

20 st cancer cells 17beta-oestradiol (E2)-bound oestrogen receptor alpha (ER-alpha) causes a global incr

21 liferation, decreased apoptosis and elevated oestrogen receptor alpha (ERalpha) expression.

22 functions as a coactivator of the endogenous oestrogen receptor alpha (ERalpha) in breast cancer cell

23 Oestrogen receptor alpha (ERalpha) is a nuclear receptor

24 The oestrogen receptor alpha (ERalpha) is expressed in prost

25 Previous studies suggest oestrogen receptor alpha (ERalpha) is involved in oestro

26 Oestrogen, often via oestrogen receptor alpha (ERalpha) signalling, regulates

27 crine therapies target the activation of the oestrogen receptor alpha (ERalpha) via distinct mechanis

28 els to show that MAF directly interacts with oestrogen receptor alpha (ERalpha), thereby promoting a

29 nipulation and in vivo recording reveal that oestrogen receptor alpha (ESR1)-expressing cells in the

30 says and supershift assays using recombinant oestrogen receptor alpha and anti-oestrogen receptor ant

31 cally, the differential interactions between oestrogen receptor alpha and other oncogenic transcripti

32 r clinical studies have linked response with oestrogen receptor alpha expression and other biomarkers

33 nor FGFR2 allele associates most strongly in oestrogen receptor alpha positive (ERalpha) breast tumou

34 light the essential elements of the membrane oestrogen receptor alpha, noting where conserved aspects

35 ly, CB sparks the constitutive activation of oestrogen receptors alpha (ERalpha) in AI-resistant cell

36 Oestrogen receptor-alpha (ER) is the defining and drivin

37 The hormone receptor oestrogen receptor-alpha (ER) orchestrates physiological

38 ects via the cytosolic and nuclear receptors oestrogen receptor-alpha (ERalpha) and oestrogen recepto

39 ime, we present a genome-wide global view of oestrogen receptor-alpha (ERalpha) binding events in the

40 or (PR) expression is used as a biomarker of oestrogen receptor-alpha (ERalpha) function and breast c

41 ified a direct interaction between Hippo and oestrogen receptor-alpha (ERalpha) signalling.

42 its effects through the transcription factor oestrogen receptor-alpha (ERalpha)(9).

43 se range of transcription factors, including oestrogen receptor-alpha (ERalpha).

44 opoietic stem cells expressed high levels of oestrogen receptor-alpha (ERalpha).

45 pathway connecting E-cadherin, beta-catenin, oestrogen receptor-alpha and GRPR that promotes melanoma

46 Inhibiting this pathway by targeting GRPR or oestrogen receptor-alpha reduces metastasis in mice, ind

47 wledge on the extensively researched markers oestrogen receptor-alpha, progesterone receptor, HER2, a

48 ation-associated breast cancer originates in oestrogen receptor-alpha-negative (ER(-)) progenitors in

49 s with negligible affinities for the nuclear oestrogen receptor also strongly inhibited high K(+)-ind

50 Most breast tumours express the oestrogen receptor and are treated with systemic therapi

51 and FOXM1, and is inversely correlated with oestrogen receptor and directly correlated with FOXM1 in

52 e show that the ability of SRC-1 to bind the oestrogen receptor and enhance its transcriptional activ

53 goal was to establish a new method to assign oestrogen receptor and ERBB2-receptor status to breast c

54 age, radiotherapy intent, nodal status, and oestrogen receptor and HER-2 status.

55 Vitamin D receptor, oestrogen receptor and mineralocorticoid receptor modula

56 st-line treatment), hormone receptor status (oestrogen receptor and progesterone receptor positive vs

57 by ERBB2), activation of hormone receptors (oestrogen receptor and progesterone receptor) and/or BRC

58 sources and the model was further tested in oestrogen receptor and progesterone receptor-labelled im

59 In the mouse ovary, oestrogen receptors and FOXL2 protect ovarian granulosa

60 ks, and stratified by previous chemotherapy, oestrogen-receptor and progesterone-receptor status, and

61 KBP12.6-null mice treated with tamoxifen, an oestrogen receptor antagonist, develop cardiac hypertrop

62 4.1 expression reduced in the presence of an oestrogen receptor antagonist, Fulvestrant 182,780 sugge

63 The development of more potent selective oestrogen receptor antagonists and degraders (SERDs) tha

64 s inhibitor, an RNA synthesis inhibitor, and oestrogen receptor antagonists did not affect the inhibi

65 including aromatase inhibitors and selective oestrogen receptor antagonists) and exogenous gonadotrop

66 ecombinant oestrogen receptor alpha and anti-oestrogen receptor antibody localized the sequence motif

67 The discovery of oestrogen receptor beta (ERbeta/ESR2) was a landmark dis

68 eport the three-dimensional structure of the oestrogen receptor beta isoform (ERbeta) ligand-binding

69 In addition, oestrogen receptor beta ligand treatment caused an incre

70 Oestrogen receptor beta ligand treatment of experimental

71 ings show a direct neuroprotective effect of oestrogen receptor beta ligand treatment on oligodendroc

72 resent study we investigated the capacity of oestrogen receptor beta ligand treatment to affect callo

73 inated axons with intact nodes of Ranvier in oestrogen receptor beta ligand-treated mice.

74 -oestradiol, which induces proliferation via oestrogen receptor-beta (ER-beta), the catecholoestradio

75 ptors oestrogen receptor-alpha (ERalpha) and oestrogen receptor-beta (ERbeta) and membrane subpopulat

76 ning residues -658 to -1 modified to abolish oestrogen receptor binding at this site, confirmed the f

77 es and rearrangement hotspots correlate with oestrogen receptor binding in breast cancer cells.

78 actions enriched for both enhancer marks and oestrogen receptor-binding sites.

79 known that male reproductive tissues express oestrogen receptors, but the role of oestrogen in male r

80 pective of age, menopausal status, or tumour oestrogen-receptor concentration (hazard ratio [HR] for

81 patients' age, menopausal status, and tumour oestrogen-receptor concentration.

82 Older women tend to have higher tumour oestrogen-receptor concentrations and are more likely to

83 e them to age, menopausal status, and tumour oestrogen-receptor concentrations.

84 has 54% homology at the protein level to the oestrogen receptor corepressor REA (repressor of oestrog

85 se mutations in patients receiving selective oestrogen receptor degrader (SERD) therapy.

86 We investigated whether the selective oestrogen receptor degrader fulvestrant could improve pr

87 nd the druggable proteome, and the selective oestrogen receptor degrader fulvestrant served as an ear

88 PI3K, AKT, and HER2, and a new generation of oestrogen-receptor degraders.

89 nin to the ligand-binding domain of a mutant oestrogen receptor (DeltaNbeta-cateninER).

90 ormonal agents, the aromatase inhibitors and oestrogen-receptor downregulators, which have no oestrog

91 The oestrogen receptor (ER or ERalpha), a nuclear hormone re

92 o the hormone-binding domain of the modified oestrogen receptor (ER(TAM)) can be regulated by provisi

93 Oestrogen receptor (ER) alpha is a well established prog

94 Crosstalk between the oestrogen receptor (ER) and ERBB2/HER-2 pathways has lon

95 INCX upregulation by E2 was blunted by an oestrogen receptor (ER) antagonist (fulvestrant, 1 mum),

96 ICI 182 780 is a pure steroidal oestrogen receptor (ER) antagonist that blocks oestrogen

97 LGSOC cases demonstrated uniformly high oestrogen receptor (ER) expression, but variable progest

98 Oestrogen receptor (ER) is a good prognostic marker for

99 stry are more likely to have young-onset and oestrogen receptor (ER) negative breast cancer for reaso

100 Here we report that human Oestrogen Receptor (ER) negative breast carcinomas which

101 A significant proportion of patients with oestrogen receptor (ER) positive breast cancers (BC) dev

102 In oestrogen receptor (ER) positive breast epithelial cells

103 Stronger associations with survival in oestrogen receptor (ER) positive disease were observed.

104 Oestrogen receptor (ER) positive tumour-derived cell lin

105 ith different survival patterns according to oestrogen receptor (ER) status.

106 ession of the progesterone receptor (PR) and oestrogen receptor (ER) was associated with subtype-spec

107 ated the effects of BAG-1 on function of the oestrogen receptor (ER), a key growth control molecule a

108 tor-1 (SRC-1), a coregulatory protein of the oestrogen receptor (ER), has previously been shown to ha

109 ancer subtypes in 690 Irish women with known oestrogen receptor (ER), progesterone receptor (PR), and

110 defined by the expression of three receptors-oestrogen receptor (ER), progesterone receptor and human

111 trogen agents inevitably occurs, mediated by oestrogen receptor (ER)-dependent or ER-independent mech

112 1, was significantly associated with risk of oestrogen receptor (ER)-negative breast cancer (odds rat

113 significant associations (P<5 x 10(-8)) with oestrogen receptor (ER)-negative breast cancer and BRCA1

114 scent staining of tumour sections from human oestrogen receptor (ER)-negative breast cancer patients

115 PHGDH protein levels are elevated in 70% of oestrogen receptor (ER)-negative breast cancers.

116 nt of axillary nodes, 276 (33%) patients had oestrogen receptor (ER)-negative disease, and 191 (27%)

117 rs of breast cancer survival involving 1,804 oestrogen receptor (ER)-negative patients treated with c

118 Women with early-stage oestrogen receptor (ER)-positive (ER(+)) breast cancer w

119 herapy improves clinical outcome in advanced oestrogen receptor (ER)-positive breast cancer, however

120 More aggressive and therapy-resistant oestrogen receptor (ER)-positive breast cancers remain a

121 For women with oestrogen receptor (ER)-positive early breast cancer, tr

122 UNX1 expression did not influence outcome of oestrogen receptor (ER)-positive or HER2-positive diseas

123 in women with aromatase inhibitor-resistant oestrogen receptor (ER)-positive, HER2-negative advanced

124 eptor modulator, was evaluated in women with oestrogen receptor (ER)-positive, HER2-negative, and and

125 d >=18 years) with histologically confirmed, oestrogen receptor (ER)-positive, HER2-negative, stage I

126 investigate the role of the top prioritized oestrogen receptor (ER)-regulated lncRNA, DSCAM-AS1.

127 Oestrogen receptor (ER)-rich patients (>=20 fmol/mg prot

128 se biological effects through binding to the oestrogen receptor (ER).

129 activity of nuclear receptors including the oestrogen receptor (ER).

130 -inducible nuclear transcription factor, the oestrogen receptor (ER).

131 ted by a specific amino acid sequence of the oestrogen receptor (ER).

132 mines tamoxifen sensitivity by regulation of oestrogen receptor (ER)alpha.

133 as no effect for breast cancers negative for oestrogen receptor (ER; hazard ratio 1.22 [0.89-1.67]; p

134 isting of 60 genes for patients positive for oestrogen receptors (ER) and 16 genes for ER-negative pa

135 sodilatory effect by binding to its specific oestrogen receptors (ER) in target cells, resulting in i

136 The interaction between oestrogen receptors (ER) in the lung and epidermal growt

137 Some oestrogen-receptor (ER) positive breast cancers express

138 expression profiling studies have shown that oestrogen-receptor (ER)-positive and ER-negative breast

139 ow-up is especially important for those with oestrogen-receptor (ER)-positive breast cancers, which c

140 Three patients with oestrogen-receptor (ER)-positive, human epidermal growth

141 culating tumour cells in women with advanced oestrogen-receptor (ER)-positive/human epidermal growth

142 ith hormone-receptor-positive breast cancer (oestrogen receptor [ER] positive, progesterone receptor

143 IRT1 and orthologous sirtuins coactivate the oestrogen receptor/ER and the worm steroid receptor DAF-

144 simultaneously increased Ca(2+) currents via oestrogen receptor ERalpha.

145 5 nm) but not the beta- (DPN, 5 nm) subtype oestrogen receptor (ERalpha/ERbeta) upregulated I(Ca,L)

146 use pancreatic beta-cells from wild-type and oestrogen receptor ERbeta-/- mice, we found that exposur

147 jority (about 75%) of breast cancers express oestrogen receptors (ERs)(3), and patients with these tu

148 (beta-ARs) and independently of the classic oestrogen receptors (ERs).

149 er samples to assess the correlation between oestrogen receptor (ESR1) and ERBB2 mRNA and clinical st

150 Expression of oestrogen receptor (ESR1) determines whether a breast ca

151 ment of oestrodial metabolizing genes or the oestrogen receptors (Esr1 and 2) in tumour multiplicity.

152 the adult virgin gland is restricted to the oestrogen receptor-expressing luminal cell lineage.

153 Our data also demonstrate that the oestrogen receptor-expressing, milk and basal cell subpo

154 cT1cN0) or II (cT1cN1, cT2cN0-1, or cT3cN0), oestrogen receptor expression of less than 1%, and proge

155 in that they are characterised by a lack of oestrogen receptor expression, contain extensive squamou

156 in that they are characterised by a lack of oestrogen receptor expression, contain extensive squamou

157 ncer overall, and by tumour histology and by oestrogen receptor expression.

158 Induction of the Myc-oestrogen receptor fusion protein (MycER) by 4-OH-tamoxi

159 s carrying EBV encoding a conditional EBNA3C-oestrogen receptor-fusion revealed that this epigenetic

160 dentify recurrent rearrangements between the oestrogen receptor gene ESR1 and its neighbour CCDC170,

161 ntly shown to activate the G protein-coupled oestrogen receptor (GPER) in vascular cells.

162 ell as the 7-transmembrane G protein-coupled oestrogen receptor (GPER).

163 target the dependence of this subtype on the oestrogen receptor have substantial activity, yet the de

164 The oestrogen receptor is a member of the nuclear receptor f

165 easible in Tanzania, and performance for the oestrogen receptor is robust.

166 benzothiophene derivative that binds to the oestrogen receptor, is a selective oestrogen receptor mo

167 Oestrogens and oestrogen receptor ligands are promising treatments to p

168 forms an alternative mechanism of activating oestrogen receptor-mediated transcription.

169 al research defined the concept of selective oestrogen receptor modulation in the 1980s.

170 Tamoxifen is a selective oestrogen receptor modulator widely used for the treatme

171 ds to the oestrogen receptor, is a selective oestrogen receptor modulator, producing oestrogen-agonis

172 uptors) and licensed drugs such as selective oestrogen receptor modulators (SERMs) and downregulators

173 We assessed the effectiveness of selective oestrogen receptor modulators (SERMs) on breast cancer i

174 e prevention trials comparing four selective oestrogen receptor modulators (SERMs; tamoxifen, raloxif

175 s (log P ~4-7), comprising several selective oestrogen receptor modulators and a modified testosteron

176 iological effects of oestrogen and selective oestrogen receptor modulators of potential cardiovascula

177 rapy (aromatase inhibitors only vs selective oestrogen receptor modulators only vs both therapies), a

178 ment of chemical cousins, known as selective oestrogen receptor modulators.

179 ds heralded the development of the selective oestrogen-receptor modulators (SERM).

180 Two selective oestrogen-receptor modulators--tamoxifen and raloxifene-

181 ne therapy was more strongly associated with oestrogen receptor negative (1.44 [1.11 to 1.88]) and tr

182 as an additional subgroup, characterised as oestrogen receptor negative and androgen receptor positi

183 e new standard of care for HER2-positive and oestrogen receptor negative breast cancer, even for pati

184 n receptor positive disease and about two in oestrogen receptor negative disease.

185 ssociated with bone relapse in patients with oestrogen-receptor negative breast cancer.

186 estrogen-receptor positive) and MDA-MB-231, (oestrogen-receptor negative) were made resistant to doce

187 east cancer, especially if the recurrence is oestrogen-receptor negative.

188 =0.05), but no effect was noted for invasive oestrogen receptor-negative breast cancer (HR 1.05 [95%

189 tingham-HES; n=1650), Nottingham early stage oestrogen receptor-negative breast cancer adjuvant chemo

190 In patients with oestrogen receptor-negative breast cancer with high SPAG

191 oxic chemotherapy sensitivity, especially in oestrogen receptor-negative breast cancer.

192 D comprised patients with AKT1 mutations and oestrogen receptor-negative cancer or PTEN mutation (tre

193 The association is stronger for oestrogen receptor-negative disease (OR 0.34, 95% CI 0.2

194 oestrogen receptor-positive disease than for oestrogen receptor-negative disease (p<0.01 for both com

195 oestrogen receptor-positive disease than for oestrogen receptor-negative disease and for lobular than

196 who did not receive chemotherapy (Nottingham-oestrogen receptor-negative-ACT cohort: HR 0.37, 95% CI

197 cer adjuvant chemotherapy cohort (Nottingham-oestrogen receptor-negative-ACT; n=697), the Nottingham

198 3 (0.69-1.00, p=0.05) when 122 patients with oestrogen-receptor-negative disease were excluded.

199 significantly more effective for women with oestrogen-receptor-negative ILRR (pinteraction=0.046), b

200 sing a chimaeric p53 fusion protein with the oestrogen receptor (p53ER) to supply p53 (p53 is induced

201 For older women with oestrogen-receptor-poor tumours who did not receive tamo

202 nd mortality in postmenopausal patients with oestrogen receptor positive (ER+) breast cancer (BC), bu

203 nal candidate, rs4442975, is associated with oestrogen receptor positive (ER+) disease with an odds r

204 esponse to endocrine therapy and survival in oestrogen receptor positive breast cancer is a significa

205 sponders and non-responders in patients with oestrogen receptor positive breast cancer.

206 patient group, by a factor of about three in oestrogen receptor positive disease and about two in oes

207 resected unilateral breast cancer (that was oestrogen-receptor positive or of unknown status), who w

208 Breast cancer cells, MCF-7 (oestrogen-receptor positive) and MDA-MB-231, (oestrogen-

209 081), especially in participants known to be oestrogen receptor-positive (0.22, 0.78-0.65, p<0.0001).

210 mutations in breast cancer, specifically in oestrogen receptor-positive (ER(+)) tumours.

211 tion of phenotypes in concordance with human oestrogen receptor-positive (ER+) breast cancer samples,

212 lationship between mutations and response of oestrogen receptor-positive (ER+) breast cancer to aroma

213 ions leading to the more aggressive forms of oestrogen receptor-positive (ER+) breast cancers is of c

214 Approvals for oestrogen receptor-positive advanced breast cancer inclu

215 patients were enrolled on the basis of their oestrogen receptor-positive and HER2-negative biomarker

216 ression-free survival in women with advanced oestrogen receptor-positive and HER2-negative breast can

217 2 study, postmenopausal women with advanced oestrogen receptor-positive and HER2-negative breast can

218 atest reduction in risk was seen in invasive oestrogen receptor-positive breast cancer (HR 0.66 [95%

219 al evidence of growth-inhibitory activity in oestrogen receptor-positive breast cancer cells and syne

220 argeted therapies for patients with advanced oestrogen receptor-positive breast cancer has improved s

221 t of 13 different types of cancer, including oestrogen receptor-positive breast cancer in postmenopau

222 Poor-prognosis oestrogen receptor-positive breast cancer is characteris

223 Invasive oestrogen receptor-positive breast cancer was reduced by

224 n three genomic regions focally amplified in oestrogen receptor-positive breast cancer, 8p11-12, 11q1

225 issue, aberrant production of which promotes oestrogen receptor-positive breast cancer.

226 androgen receptor is a tumour suppressor in oestrogen receptor-positive breast cancer.

227 C comprised patients with AKT1 mutations and oestrogen receptor-positive cancer (treated with oral ca

228 ive disease (OR 0.34, 95% CI 0.21-0.54) than oestrogen receptor-positive disease (OR 0.63, 95% CI 0.4

229 enous ovarian hormones are more relevant for oestrogen receptor-positive disease than for oestrogen r

230 trends by age at menopause were stronger for oestrogen receptor-positive disease than for oestrogen r

231 analysis showed a stronger association with oestrogen receptor-positive disease.

232 cells and also, although at lower levels, in oestrogen receptor-positive luminal cells.

233 dose (1.7 micromol kg(-1), 1 T), but not in oestrogen receptor-positive MCF-7 tumours.

234 gible patients with histologically confirmed oestrogen receptor-positive or progesterone receptor-pos

235 l to improve outcomes in women with operable oestrogen receptor-positive primary breast cancer.

236 nhances oestrogen-dependent transcription in oestrogen receptor-positive tumour cells and promotes th

237 e increased risk appears largely confined to oestrogen receptor-positive tumour risk.

238 node positive disease, and 4330 (82.7%) had oestrogen receptor-positive tumours.

239 (treated with oral neratinib 240 mg, and if oestrogen receptor-positive with intramuscular standard-

240 ant can improve progression-free survival in oestrogen receptor-positive, endocrine-resistant breast

241 ically confirmed metastastic or locoregional oestrogen receptor-positive, HER2-negative breast cancer

242 lopment of camizestrant for the treatment of oestrogen receptor-positive, HER2-negative breast cancer

243 menopausal women aged 18 years or older with oestrogen receptor-positive, HER2-negative breast cancer

244 st-line treatment of patients with advanced, oestrogen receptor-positive, HER2-negative breast cancer

245 Oncology Group performance status of 0-2 and oestrogen receptor-positive, HER2-negative, metastatic o

246 tage (cT)1c to cT4a-c (>=1.5 cm within cT1c) oestrogen receptor-positive, HER2-negative, untreated ea

247 stmenopausal women with early stage hormone (oestrogen) receptor-positive invasive breast cancer were

248 Oestrogen-receptor-positive (ER(+)) BCa requires oestrog

249 ence single normal and tumour nuclei from an oestrogen-receptor-positive (ER(+)) breast cancer and a

250 o oestrogen-deprivation therapy is common in oestrogen-receptor-positive (ER+) breast cancer.

251 These include a high-risk, oestrogen-receptor-positive 11q13/14 cis-acting subgroup

252 has been made in identifying the drivers of oestrogen-receptor-positive breast cancer and the mechan

253 Distinct phenotypes in oestrogen-receptor-positive breast cancer are associated

254 e bank from all postmenopausal patients with oestrogen-receptor-positive breast cancer from whom the

255 Oestrogen-receptor-positive breast cancer is the most co

256 for postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer showed that ch

257 is prognostic for women with node-negative, oestrogen-receptor-positive breast cancer treated with t

258 correlate the variable clinical features of oestrogen-receptor-positive breast cancer with somatic a

259 therapy for late recurrence in patients with oestrogen-receptor-positive breast cancer would be clini

260 of the remaining cancers (p(cohort)<0.050): oestrogen-receptor-positive breast cancer, uterine corpu

261 e replacement therapy, either overall or for oestrogen-receptor-positive disease.

262 after tamoxifen in postmenopausal women with oestrogen-receptor-positive early breast cancer.

263 Patients with oestrogen-receptor-positive ILRR received adjuvant endoc

264 enopausal patients with unilateral invasive, oestrogen-receptor-positive or oestrogen-receptor-unknow

265 An ESR1 mRNA cutoff value of 500 identified oestrogen-receptor-positive status with an overall accur

266 s showed that tamoxifen benefited women with oestrogen-receptor-positive tumours and negative axillar

267 has been achieved in treatment of women with oestrogen-receptor-positive tumours and negative nodes.

268 patients with early stage breast cancer and oestrogen-receptor-positive tumours.

269 tissue was available from 665 patients with oestrogen-receptor-positive, N0 breast cancer for BCI an

270 h early and late recurrence in patients with oestrogen-receptor-positive, node-negative (N0) disease

271 Because 90% of tumours are oestrogen-receptor-positive, tamoxifen is standard adjuv

272 ch tumour cells do not express the genes for oestrogen receptor, progesterone receptor and HER2 (also

273 cers and to establish if these are linked to oestrogen receptor, progesterone receptor, and human epi

274 ta will be available for how factors such as oestrogen receptor, progesterone receptor, HER2, and ind

275 s focused on women with tumours positive for oestrogen receptor, progesterone receptor, or both.

276 Because tamoxifen-an oestrogen receptor regulator-reduced signs of muscular p

277 In female mice, progesterone-guided oestrogen receptor signalling maintained ERRalpha activi

278 sis indicated the Galphai signalling and the oestrogen receptor signalling to be similarly affected i

279 g LINC00160 expressions and interaction with oestrogen receptor signalling.

280 orted by systemic therapy appropriate to the oestrogen receptor status (ER) of the tumour, local radi

281 M0 disease and those with incomplete data on oestrogen receptor status, progesterone receptor status,

282 involved axillary lymph nodes, tumour stage, oestrogen receptor status, type and timing of systemic t

283 GeneChip reliably and reproducibly establish oestrogen-receptor status and ERBB2 status, respectively

284 nd might be used at the same time to confirm oestrogen-receptor status and ERBB2 status.

285 es of disease-free survival according to the oestrogen-receptor status of the primary tumour were not

286 known prognostic factors (age, nodal status, oestrogen-receptor status, grade, and tumour size).

287 axillary lymph nodes, clinical tumour stage, oestrogen-receptor status, type and timing of systemic t

288 after control for tumour grade, tumour size, oestrogen-receptor status, vascular invasion, and treatm

289 e effects for NSMP cancers were modulated by oestrogen-receptor status.

290 zoledronic acid on DFS were not affected by oestrogen-receptor status.

291 ment induces DNA double-strand breaks in the oestrogen receptor target regions that are repaired by t

292 The oestrogen receptor targets LLGL2 expression.

293 )-inducible telomerase reverse transcriptase-oestrogen receptor (TERT-ER) under transcriptional contr

294 idues in a conserved helix (helix 12) of the oestrogen receptor that are required for its ligand-indu

295 TRIM24 binds chromatin and oestrogen receptor to activate oestrogen-dependent genes

296 are also present in HM and can interact with oestrogen receptors to interfere with normal hormone fun

297 thalamus, ventrolateral subdivision contains oestrogen receptor type 1-positive neurons that control

298 ral invasive, oestrogen-receptor-positive or oestrogen-receptor-unknown breast cancer who were diseas

299 tibody localized the sequence motif to which oestrogen receptor was binding to residues -225 to -212

300 Fusions of the ligand-binding domain of the oestrogen receptor with the DBD of RFX4 occur in some hu